Glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions

Interventional Cardiology

Volumn 2, Issue 3, 2010, Pages 301-318

  Koutouzis, Michael ^a   Grip, Lars ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

abciximab; eptifibatide; glycoprotein IIb IIIa inhibitor; myocardial infarction; percutaneous coronary intervention; tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOTRAFIBAN; ORBOFIBAN; RETEPLASE; ROXIFIBAN; SIBRAFIBAN; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; TIROFIBAN; XEMILOFIBAN;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DIABETIC PATIENT; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; INFLAMMATION; LOW DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; REVIEW; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS; VEIN GRAFT;

EID: 77954094595     PISSN: 17555302     EISSN: 17555310     Source Type: Journal    
DOI: 10.2217/ica.10.33     Document Type: Review

References (105)

1. Barnathan ES, Schwartz JS, Taylor L et al.: Aspirin and dipryidamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 76(1), 125-134 (1987).
2. Detre KM, Holmes Jr DR, Holubkov R et al.: Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute percutaneous transluminal coronary angioplasty registry. Circulation 82(3), 739-750 (1990). (Pubitemid 20316724)
3. Harker LA: Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am. J. Cardiol. 60(3), B20-B28 (1987).
4. Leung L, Nachman R: Molecular mechanisms of platelet aggregation. Annu. Rev. Med. 37, 179-186 (1986).
5. Phillips DR, Charo IF, Parise LV, Fitzgerald LA: The platelet membrane glycoprotein IIb-IIa complex. Blood 71(4), 831-843 (1988).
6. Coller BS: A new murine monoclonal antibody reports an activation-dependent ahange in the conformation and/or microenvironment of the platelet glycoprotein lIb/Illa complex. J. Clin. Invest. 76(1), 101-108 (1985).
7. Ellis SG, Tcheng JE, Navetta FI et al.: Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coron. Artery Dis. 4(2), 167-175 (1993).
8. Mascelli M, Lance E, Damaraju L et al.: Pharmacodynamic profle of short term abciximab treatment demonstrates prolong platelet inhibition with gradual recovery from GPIIb/IIIa blockade. Circulation 97(17), 1680-1688 (1998).
9. Simon DI, XU H, Ortlepp S, Rogers C, Rao NK: 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fbrinogen and ICAM-1. Arterioscler. Thromb. Vasc. Biol. 17(3), 528-535 (1997).
10. Tam SH, Sassoli PM, Jordan RE et al.: Abciximab, chimeric 7E3 Fab demonstrates equivalent affnity and functional blockade of glycoprotein IIb/IIIa and a(v)b3 integrins. Circulation 98(11), 1085-1091 (1998).
11. Scarborough RM: Development of eptifbatide. Am. Heart J. 138(6 Pt 1), 1093-1104 (1999).
12. Kereiakes DJ, Kleiman NS, Ambrose J et al.: Randomized, double blind, placebo controlled dose ranging study of tirofban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J. Am. Coll. Cardiol. 27(3), 536-542 (1996).
13. Antman EM, Hand M, Armstrong PW et al.: 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 51(2), 210-247 (2008).
14. Anderson JL, Adams CD, Antman EM et al.: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 50(7), E1-E157 (2007).
15. Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al.: ACC/AHA/SCAI 2005 Guideline Update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 47(1), 216-235 (2006).
16. van de Werf F, Bax J, Betriu A et al.: Management of acute myocardial infarction in patients with persistent ST-segment elevation. Eur. Heart J. 29(23), 2909-2945 (2008).
17. Bassand JP, Hamm CW, Ardissino D et al.: Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 28(13), 1598-1660 (2007).
18. Fox K, Garcia MA, Ardissino D et al.: Guidelines for the management of stable angina pectoris: executive summary. The task force on the management of stable angina pectoris of the European Society of Cardiology. Eur. Heart J. 27(11), 1341-1381 (2006) (Pubitemid 43998110)
19. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med. 330(14), 956-961 (1994).
20. Aguirre FV, Topol EJ, Ferguson JJ et al.: Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 91(12), 2882-2890 (1995)
21. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N. Engl. J. Med. 336(24), 1689-1696 (1997).
22. The CAPTURE investigators: Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 349(9063), 1429-1435 (1997).
23. Hamm CW, Heeschen C, Goldmann B et al.; for the c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators: Beneft of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N. Engl. J. Med. 340(21), 1623-1629 (1999).
24. The EPISTENT Investigators: Randomized placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352(9122), 87-92 (1998).
25. Steinhubl SR, Ellis SG, Wolski K et al.: Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events. Circulation 103(10), 1403-1409 (2001).
26. Kastrati A, Mehilli J, Schühlen H et al.: A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N. Engl. J. Med. 350(3), 232-238 (2004).
27. Kastrati A, Mehilli J, Neumann FJ et al.: Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. JAMA 295(13), 1531-1538 (2006).
28. The IMPACT-II investigators: Randomised placebo-controlled trial of effect of eptifbatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 349(9063), 1422-1428 (1997)
29. The PURSUIT Trial Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifbatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N. Engl. J. Med. 339(7), 436-443 (1998).
30. The ESPRIT Investigators: A randomised, placebo-controlled trial of a novel dosing regimen of eptifbatide in planned coronary stent implantation. Lancet 356(9247), 2037-2044 (2000).
31. Giugliano RP, White JA, Bode C et al.; for the EARLY ACS Investigators: Early versus delayed, provisional eptifbatide in acute coronary syndromes. N. Engl. J. Med. 360(21), 2176-2190 (2009).
32. The RESTORE Investigators: Effects of platelet glycoprotein IIb/IIIa blockade with tirofban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Effcacy Study of Tirofban for Outcomes and Restenosis. Circulation 96(5), 1445-1453 (1997).
33. Rasoul S, Ottervanger JP, de Boer MJ et al.: A comparison of dual vs. triple antiplatelet treatment in patients with non ST elevation acute coronary syndrome: results from the ELISA 2 trial. Eur. Heart J. 27(12), 1401-1407 (2006).
34. Cannon CP, McCabe CH, Wilcox RG et al.: Oral Glycoprotein IIb/IIIa Inhibition With Orbofban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. Circulation 102(2), 149-156 (2000).
35. O'Neil WW, Serruys P, Knudtson M et al.: Long term treatment with platelet glycoprotein receptor antagonist after percutaneous coronary revascularization. N. Engl. J. Med. 342(18), 1316-1324 (2000).
36. Sobel M, Salzman EW, Davies GC et al.: Circulating platelet products in unstable angina pectoris. Circulation 63(2), 300-306 (1981).
37. Kristensen SD, Bath PMW, Martin JF: Differences in bleeding time, aspirin sensitivity and adrenaline between acute myocardial infarction and unstable angina. Cardiovasc. Res. 24(1), 19-23 (1990).
38. Brener SJ, Barr LA, Burchenal JE et al.: Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 98(8), 734-741 (1998).
39. Montalescot G, Barragan P, Wittenberg O et al.: Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N. Engl. J. Med. 344(25), 1895-1903 (2001). (Pubitemid 32553358)
40. Antoniucci D, Migliorini A, Parodi G et al.: Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation 109 (14), 1704-11406 (2004).
41. Stone GW, Grines CL, Cox DA et al.: Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N. Engl. J. Med. 346(13), 957-966 (2002).
42. de Luca G, Suryapranata H, Stone GW et al.: Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-ana lysis of randomized trials. JAMA 293 (14), 1759-1765 (2005).
43. de Luca G, Navarese E, Marino P: Risk profle and benefts from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression ana lysis of randomized trials. Eur. Heart J. 30(22), 2705-2713 (2009).
44. Mehilli J, Kastrati A, Schulz S et al.; for the Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) Study Investigators: Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 119(14), 1933-1940 (2009).
45. Van't Hof AW, Ten Berg J, Heestermans T et al.: Prehospital initiation of tirofban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Ongoing Tirofban In Myocardial infarction Evaluation (On-TIME) 2 study group. Lancet 372(9638), 537-546 (2008).
46. van den Merkhof LF, Zijlstra F, Olsson H et al.: Abciximab in the treatment of acute myocardial eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J. Am. Coll. Cardiol. 33(6), 1528-1532 (1999).
47. Montalescot G, Borentain M, Payot L et al.: Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-ana lysis. JAMA 292(3), 362-366 (2004).
48. Gödicke J, Flather M, Noc M et al.: Early versus periprocedural administration of abciximab for primary angioplasty: a pooled ana lysis of 6 studies. Am. Heart J. 150(5), 1015.e11-1015.e17 (2005).
49. Gibson CM, Kirtane AJ, Murphy SA et al.: Early initiation of eptifbatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am. Heart J. 152(4), 668-675 (2006).
50. Zeymer U, Zahn R, Schiele R et al.: Early eptifbatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized Integrilin in Acute Myocardial Infarction (INTAMI) pilot trial. Eur. Heart J. 26(19), 1971-1977 (2005).
51. Ellis SG, Tendera M, de Belder MA et al.; FINESSE Investigators: Facilitated PCI in patients with ST-elevation myocardial infarction. N. Engl. J. Med. 358(21), 2205-2217 (2008).
52. Topol EJ, Moliterno DJ, Herrmann HC et al.; for the TARGET Investigators: Do tirofban and ReoPro give similar effcacy trial: comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med. 344(25), 1888-1894 (2001).
53. Marzocchi A, Manari A, Piovaccari G et al.: Randomized comparison between tirofban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofban or abciximab (FATA) in ST-elevation myocardial infarction trial. Eur. Heart J. 29(24), 2972-2980 (2008).
54. Valgimigli M, Campo G, Percoco G et al.; Multicentre Evaluation of Single High-Dose Bolus Tirofban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators: Comparison of angioplasty with infusion of tirofban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 299(15), 1788-1799 (2008).
55. Zeymer U: Eptifbatide versus abciximab in primary PCI for acute ST elevation myocardial infarction. EVA-AMI Trial. Presented at: Scientifc Sessions of the AHA, Late-breaking Clinical Trials 1. Orlando, FL, USA, 4 November 2007.
56. de Luca G, Ucci G, Cassetti E et al.: Benefts from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-ana lysis. J. Am. Coll. Cardiol. 53(18), 1668-1673 (2009).
57. Coons JC, Seybert AL, Saul MI et al.: Outcomes and costs of abciximab versus eptifbatide for percutaneous coronary interventions. Ann. Pharmacother. 39(10), 1621-1626 (2005).
58. Long KH, Ting HH, McMurtry EK et al.: A longitudinal ana lysis of outcomes associated with abciximab and eptifbatide in a consecutive series of 3074 percutaneous coronary interventions. Value Health 11(3), 462-469 (2008).
59. Deliargyris EN, Upadhya B, Applegate RG et al.: Superior in hospital and 30 day outcomes with abciximab versus eptifbatide: a contemporary ana lysis of 495 consecutive percutaneous coronary interventions. J. Invasive Cardiol. 16(11), 611-616 (2004).
60. Schweiger MJ, Changezi HU, Naglieri-Prescod D et al.: Open-label, sequential comparison of eptifbatide with abciximab for patients undergoing percutaneous coronary interventions. Clin. Ther. 25(1), 225-234 (2003).
61. Leung V W, Sunderji R, Zed PJ et al.: Switching from abciximab to eptifbatide for percutaneous coronary interventions: a local ana lysis (SWAP study). Can. J. Cardiol. 19(7), 809-814 (2003).
62. Wahlin M, Albertsson P, Karlsson T et al.: Switch from abciximab to eptifbatide during percutaneous coronary intervention. Int. J. Cardiol. 134(3), 393-400 (2009).
63. Åkerblom A, James SK, Koutouzis M et al.: Eptifbatide is non-inferior to abciximab in primary PCI-results from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). J. Am. Coll. Cardiol. (2010) (In press).
64. Wöhrle J, Grebe OC, Nusser T et al.: Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus aplication of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 107(14), 1840-1843 (2003).
65. Thiele H, Schindler K, Friedenberger J et al.: Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 118(1), 49-57 (2008).
66. Hassan W, Al-Sergani H, Al Buraiki J et al.: Immediate and intermediate results of intracoronary stand-alone bolus administration of eptifbatide during coronary intervention (ICE) study. Am. Heart J. 154(2), 345-351 (2007).
67. Wu TG, Zhao Q, Huang WG et al.: Effect of intracoronary tirofban in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Circ. J. 72(10), 1605-1609 (2008).
68. Urquidi-Macdonald M, Mager DE, Mascelli MA et al.: Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability. Clin. Pharmacol. Ther. 75(1), 60-69 (2004).
69. Ernst NMSKJ, Suryapranata H, Miedema K et al.: Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 44(6), 1187-1193 (2004).
70. Chew DP, Bhatt DL, Lincoff MA et al.: Defning the optimal activated clotting time during percutaneous coronary intervention. Circulation 103(7), 961-966 (2001).
71. Mandak JS, Blankenship JC, Gardner LH et al.: Modifable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifbatide. Integrilin to minimize platelet aggregation and coronary thrombosis. J. Am. Coll. Cardiol. 31(7), 1518-1524 (1998).
72. Tcheng JE: Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am. Heart J. 139(2 Pt 2), S38-S45 (2000).
73. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SM, Menapace FJ: Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors. Am. Heart J. 140(2), 206-211 (2000).
74. Merlini PA, Rossi M, Menozzi A et al.: Thrombocytopenia caused by abciximab or tirofban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 109(18), 2203-2206 (2004).
75. Tcheng JE, Kereiakes DJ, Lincoff AM et al.: Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 104(8), 870-875 (2001).
76. Lincoff MA, Kleiman NS, Kereiakes DJ et al.: Long term effcacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary interventions: REPLACE-2 randomized trial. JAMA 292(6), 696-703 (2004).
77. Stone GW, White HD, Ohman EM et al.: Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup ana lysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 369(9565), 907-919 (2007).
78. Stone GW, Witzenbichler B, Guagliumi G et al.; HORIZONS-AMI Trial Investigators: Bivalirudin during primary PCI in acute myocardial infarction. N. Engl. J. Med. 358(21), 2218-2230 (2008).
79. Marso SP, Lincoff AM, Ellis SG et al.: Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy. Circulation 100(25), 2477-2484 (1999).
80. Mehilli J, Kastrati A, Schühlen H et al.; Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators: Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110(24), 3627-3635 (2004).
81. Schühlen H, Kastrati A, Mehilli J et al.: Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT-a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. Am. Heart J. 151(6), 1248-1254 (2006).
82. Chaves AJ, Sousa AG, Mattos LA et al.: Volumetric ana lysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: results of the Diabetes Abciximab Stent Evaluation (DANTE) randomized trial. Circulation 109(7), 861-866 (2004).
83. The ERASER Investigators: Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation 100(8), 799-806 (1999).
84. Neumann FJ, Zohlnhofer D, Fakhoury L et al.: Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J. Am. Coll. Cardiol. 34(5), 1420-1426 (1999).
85. Lincoff AM, Kereiakes DJ, Mascelli MA et al.: Abciximab suppresses the rise in the levels of circulating infammatory markers after percutaneous coronary revascularization. Circulation 104(2), 163-167 (2001).
86. Åstrom-Olsson K, Hedstrom E, Mattson Hulten L et al.: Dissociation of the infammatory reaction following PCI for myocardial infarction. J. Invasive Cardiol. 19(11), 452-456 (2007).
87. Li G, Keenan AC, Young JC et al.: Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirudin on myeloperoxidase release from neutrophils. Arterioscler. Thromb. Vasc. Biol. 27, 1850-1856 (2007).
88. Abizaid, A, Costa, MA, Centemero M et al.: Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 104(5), 533-538 (2001).
89. Silber A, Albertsson P, Avilés FF et al.: Guideleines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European Society of Cardiology. Eur. Heart J. 26(8), 804-847 (2005).
90. Breddin HK, Krzywanek NHJ, Althoff P et al.: Haemostasiological parameters as risk factor for new arterial occlusions in diabetics Klin. Wochenschr. 64(20), 1042-1046 (1986).
91. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ: Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J. Am. Coll. Cardiol. 35(4), 922-928 (2000).
92. Nikolsky E, Holmes DR, Mehran R: Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on outcomes of diabetic patients undergoing percutaneous coronary interventions using sirolimus-eluting stents. Catheter Cardiovasc. Interv. 71(7), 896-906 (2008).
93. Jeremias A, Bhatt DL, Chew DP et al.: Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insuffciency. Am. J. Cardiol. 89(10), 1209-1211 (2002).
94. Frilling B, Zahn R, Fraiture B et al.: Comparison of effcacy and complication rates after percutaneous coronary interventions in patients with and without renal insuffciency treated with abciximab. Am. J. Cardiol. 89(4), 450-452 (2002).
95. Best PJ, Lennon R, Gersh BJ et al.: Safety of abciximab in patients with chronic renal insuffciency who are undergoing percutaneous coronary interventions. Am. Heart J. 146(2), 345-350 (2003).
96. Januzzi JL, Snapinn SM, DiBattiste PM et al. Benefts and safety of tirofban among acute coronary syndromes patients with mild to moderate renal insuffciency. Circulation 105(20), 2361-2366 (2002).
97. Reddan DN, O'Shea JC, Sarembock IJ et al.: Treatment effects of eprifbatide in planned stent implantation in patients with chronic kidney disease (ESPRIT trial). Am. J. Cardiol. 91(1), 17-21 (2003).
98. Piana RN, Paik GY, Moscucci M et al.: Incidence and treatment of 'no-refow' after percutaneous coronary intervention. Circulation 89(6), 2514-2518 (1994).
99. De Feyter PJ, van Suylen RJ, de Jaegere PP et al.: Balloon angioplasty for the treatment of lesions in saphenous veins by pass grafts. J. Am. Coll. Cardiol. 35(5), 1103-1115 (2000).
100. Moff M, Mukherjee D, Chew DP et al.: Lack of beneft from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled ana lysis of fve randomized clinical trials. Circulation 106(24), 3063-3067 (2002).
101. Montalescot G, Wiviott SD, Braunwald E et al.: Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TiMI 38): double-blind, randomized control trial. Lancet 373(9665), 723-731 (2009).
102. Wallentin L, Becker RC, Budaj A et al.: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045-1057 (2009)
103. TRA*CER Executive and Steering Committees: The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. Am. Heart J. 158(3), 327-334 (2009).
104. de Carlo M, Borelli G, Gistri R et al.: Effectiveness of the transradial approach to reduce bleedings in patients undergoing urgent coronary angioplasty with GPIIb/IIIa inhibitors for acute coronary syndromes. Catheter Cardiovasc. Interv. 74(3), 408-415 (2009).
105. Vlaar PJ, Svilaas T, van der Horst IC et al.: Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet 371(9628), 1915-1920 (2008).